Navigation Links
Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
Date:4/24/2008

s plus Copegus suggests that the 1000mg dose could deliver a rapid virologic response (RVR) rate similar to the 1500mg dose," stated Dr. Michelle Berrey, Pharmasset's Chief Medical Officer. "The confirmatory results from this additional cohort will aid us in selecting the appropriate doses to evaluate in the global Phase 2b study that is being planned to evaluate R7128 in triple combination for up to 12 weeks."

"R7128 is equally potent in vitro against HCV genotypes 1, 2, 3 and 4, and we believe it is clinically and commercially important to test R7128 in patients with these HCV genotypes," stated Schaefer Price, Pharmasset's Chief Executive Officer. "Twenty percent of U.S. HCV-infected patients and approximately 30% of European and Latin American HCV-infected patients have genotypes 2 and 3. These patients are currently treated with 24 weeks of pegylated-interferon plus ribavirin, but 20% of this population fails to achieve an SVR. By potentially addressing this unmet medical need in a patient population for whom the standard of care is only 24 weeks, we could possibly design shorter clinical trials that may provide a quicker path to the market for R7128."

Separately, the results of the 4-week Phase 1 clinical trial evaluating two oral dose levels of R7128 (500mg and 1500mg) in combination with Pegasys plus Copegus in 50 treatment-naive patients chronically infected with HCV genotype 1 will be presented at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) in Milan, Italy on Friday, April 25, 2008 at 11:15 AM ET (US) and 5:15 PM CEST (Milan). The scientific presentation will be available for download in PDF format immediately following the EASL presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm.

Please see '/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
2. Pharmasset Receives $10 Million of Working Capital
3. Pharmasset Appoints Herbert J. Conrad as a Director
4. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
5. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
6. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
7. Pharmasset Reports Fiscal Year End 2007 Financial Results
8. Pharmasset Appoints Michael Rogers as Chief Development Officer
9. Pharmasset to Present at Three Investor Conferences in November 2007
10. Pharmasset Accesses up to $30 Million of Working Capital
11. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 1, 2015 A new report ... drugs will reach $22.4bn in 2019. That revenue forecast ... and Market Prospects 2015-2025 ,  published in ... is to provide forecasts and qualitative analyses of the ... and consultancy in London, UK . ...
(Date:5/1/2015)... -- Albany Molecular Research Inc. (NASDAQ: AMRI ) ... President and Chief Executive Officer, will present at the ... on Wednesday, May 13, 2015 at 4:20 p.m. ET. ... can be accessed at AMRI,s Investor Relations web site at ... be archived for 90 days following the live presentation. ...
(Date:5/1/2015)... RESEARCH TRIANGLE PARK, N.C. , May 1, ... today that Roger Jeffs , Ph.D., President and Co-Chief ... update on the company,s business at the Deutsche Bank 40 ... Massachusetts . The presentation will take place ... and can be accessed via a live webcast on the ...
(Date:4/30/2015)... April 30, 2015  Roka Bioscience, Inc. (NASDAQ: ... advanced testing solutions for the detection of foodborne pathogens, ... first quarter of 2015 on May 7, 2015 after ... Bioscience will also host a conference call at 4:30 ... its first quarter financial results. During the conference call, ...
Breaking Biology Technology:Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5AMRI to Present at the Bank of America Merrill Lynch 2015 Health Care Conference 2Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2
... - 11:00 a.m. ET; 8:00 a.m. PT, VANCOUVER ... (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs ... on Tuesday,September 11, 2007 at 11:00 a.m. ET (8:00 ... quarter ended July 31, 2007. An update on,company activities ...
... Keynote Emphasizes Generic Industry Readiness and Questions Fiscal ... Social Responsibility of Delaying Biogenerics -, WASHINGTON, Sept. ... crossroads as decades-old patents,expire, and generic companies stand ready ... time to pass legislation enabling the U.S.,Food and Drug ...
... Sept. 6 NPS,Pharmaceuticals, Inc. (Nasdaq: NPSP ) ... for any and all of its outstanding 3.0% Convertible,Notes ... Eastern Time on,October 4, 2007, unless extended. The tender ... and the related letter of transmittal, is not,subject to ...
Cached Biology Technology:MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification 2Biogenerics Will Save Billions, Says Hospira CEO 2Biogenerics Will Save Billions, Says Hospira CEO 3Biogenerics Will Save Billions, Says Hospira CEO 4NPS Pharmaceuticals Commences Tender Offer for 3.0% Convertible Notes Due 2008 2NPS Pharmaceuticals Commences Tender Offer for 3.0% Convertible Notes Due 2008 3NPS Pharmaceuticals Commences Tender Offer for 3.0% Convertible Notes Due 2008 4
(Date:4/17/2015)... Canada , April 17, 2015 ... growing security concerns, and technological advancement to drive ... until 2020   According ... Saudi Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems ... is projected to register growth at CAGR of ...
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... nominated for the 2015 New York Design Awards under ... Design100, New York City Design Awards are part of ... on over 2,500 ratings from the marketplace, industry and ...
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... the most stressful thing that can happen to anybody. But ... of traumatic experiences. Most humans come to terms with it ... How weaning takes place, however, can have a dramatic effect on ... this is so, at least for horses, comes from the latest ...
... different types of animals come together to form vast groups ... Researchers in France added another example to the list, reported ... huge Wels catfish, the world,s third largest and Europe,s largest ... from May 2009 to Feb. 2011 and found that they ...
... Kansas State University research team is serving up ... and staff. Junehee Kwon, associate professor of ... professor of hospitality management and dietetics, are co-principal ... United States Department of Agriculture Higher Education Challenge ...
Cached Biology News:The short goodbye: Weaning foals 2The short goodbye: Weaning foals 3On the menu: Research helps future restaurant managers reach out to customers with food allergies 2
... HISTAR detection systems provide linking and ... with species specific primary antibodies for ... Visualisation is accomplished using an ultra-sensitive ... polymer labelling technology. Secondary antibodies are ...
... • Enzyme concentration - 5 units/µL ... in higher yields ,• Leaves an 'A' ... DNA polymerase which exhibits very high activity ... applications. To ensure the quality of the ...
... Recombinant DNA polymerase from Thermus aquaticus expressed ... contamination; 1 tube of 250 units enzyme/tube ... (Low DNA), is the same enzyme as ... through a proprietary separation process to ensure ...
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
Biology Products: